Benzinga | Jan 20, 2022 06:19AM EST

HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $350

HC Wainwright & Co. analyst Patrick Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $250 to $350.